Sign in
Active, not recruitingNo phase

Electrophysiological Outcomes After Transcatheter Aortic Valve Replacement

Key facts

Who runs it
Chinese Academy of Medical Sciences, Fuwai Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
1,000 people, planned
Started
1 Jan 2022
Expected to end
31 Dec 2026
Type of study
Observational
Treatments tested
  • TAVR Aspirin and clopidogrel
Record updated
5 February 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Age ≥18 years at the time of transcatheter aortic valve replacement (TAVR). Diagnosis of severe aortic stenosis based on current guideline-recommended echocardiographic criteria
  • Undergoing transcatheter aortic valve replacement (TAVR) as part of routine clinical care
  • Availability of baseline electrocardiographic assessment, including ambulatory electrocardiographic monitoring for evaluation of premature ventricular contraction (PVC) burden
  • Completion of post-procedural rhythm follow-up, including ambulatory electrocardiographic monitoring at 12 months after TAVR
  • Ability to provide informed consent or availability of legally authorized consent, as required by the institutional review board

Who cannot take part

  • Presence of a permanent pacemaker or implantable cardioverter-defibrillator prior to TAVR
  • Receipt of catheter ablation for atrial or ventricular arrhythmias before TAVR or during the follow-up period
  • Absence of premature ventricular contractions at baseline (PVC burden = 0), as PVC response cannot be meaningfully assessed in this population
  • Death occurring during the index hospitalization or before completion of rhythm follow-up
  • Inability to complete scheduled electrocardiographic or ambulatory rhythm assessments during follow-up
  • Missing or incomplete key electrocardiographic, echocardiographic, or follow-up data required for outcome assessment

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The TAVR-ELECTRO Registry (Electrophysiological Outcomes After Transcatheter Aortic Valve Replacement) is a single-center, observational cohort study designed to systematically evaluate the occurrence, temporal evolution, and determinants of cardiac arrhythmias following transcatheter aortic valve replacement (TAVR) in patients with severe aortic stenosis.

Read full original descriptionShow less

This registry retrospectively enrolls consecutive patients undergoing TAVR at Fuwai Hospital, Chinese Academy of Medical Sciences, and collects comprehensive clinical, echocardiographic, electrocardiographic, and procedural data. Particular emphasis is placed on post-procedural electrophysiological outcomes, including ventricular arrhythmias, atrial arrhythmias, and conduction disturbances. Serial rhythm assessments using standard electrocardiography and ambulatory electrocardiographic monitoring are performed during follow-up to characterize arrhythmic burden and its dynamic changes over time.

The primary objective of the TAVR-ELECTRO Registry is to identify clinical, haemodynamic, and procedural factors associated with post-TAVR arrhythmic outcomes and recovery patterns, thereby improving the understanding of electrophysiological remodeling after TAVR and informing post-procedural risk stratification and management strategies.

Treatments tested

  • TAVR Aspirin and clopidogrel

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
5 February 2026